Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 June 2019Website:
http://www.adaptivebiotech.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 96 min agoDividend
Analysts recommendations
Institutional Ownership
ADPT Latest News
SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies
Although the revenue and EPS for Adaptive Biotechnologies (ADPT) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.33 per share a year ago.
SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2024.
Two elements favor the case for acquiring precision medicine stocks. First, the obvious point: barring extraordinary circumstances, the broader healthcare ecosystem will always be relevant.
SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers
Adaptive Biotechnologies Corporation (ADPT) Q4 2023 Earnings Call Transcript
SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
- 1(current)
What type of business is Adaptive Biotechnologies?
Adaptive Biotechnologies Corporation is a biotechnology company that focuses on developing and commercializing a platform for discovering methods of diagnosing and treating diseases in the field of immune medicine. The company was founded in 2009 and was known as Adaptive TCR Corporation until 2011. The company is headquartered in Seattle, Washington. The company has three commercial products and is also developing a range of clinical products and services for the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune, and infectious diseases.
What sector is Adaptive Biotechnologies in?
Adaptive Biotechnologies is in the Healthcare sector
What industry is Adaptive Biotechnologies in?
Adaptive Biotechnologies is in the Biotechnology industry
What country is Adaptive Biotechnologies from?
Adaptive Biotechnologies is headquartered in United States
When did Adaptive Biotechnologies go public?
Adaptive Biotechnologies initial public offering (IPO) was on 27 June 2019
What is Adaptive Biotechnologies website?
https://www.adaptivebiotech.com
Is Adaptive Biotechnologies in the S&P 500?
No, Adaptive Biotechnologies is not included in the S&P 500 index
Is Adaptive Biotechnologies in the NASDAQ 100?
No, Adaptive Biotechnologies is not included in the NASDAQ 100 index
Is Adaptive Biotechnologies in the Dow Jones?
No, Adaptive Biotechnologies is not included in the Dow Jones index
When was Adaptive Biotechnologies the previous earnings report?
No data
When does Adaptive Biotechnologies earnings report?
The next expected earnings date for Adaptive Biotechnologies is 07 November 2024